RA Capital Management, L.P. 13D and 13G filings for Aerovate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-06-20 6:00 pm Purchase |
2024-06-17 | 13D | Aerovate Therapeutics, Inc. AVTE |
RA Capital Management, L.P. | 9,242,092 32.000% |
928,110 (+11.16%) |
Filing |
| 2024-04-30 4:16 pm Purchase |
2024-04-26 | 13D | Aerovate Therapeutics, Inc. AVTE |
RA Capital Management, L.P. | 8,313,982 28.900% |
20,834 (+0.25%) |
Filing |
| 2023-06-27 5:00 pm Purchase |
2023-06-26 | 13D | Aerovate Therapeutics, Inc. AVTE |
RA Capital Management, L.P. | 8,293,148 30.000% |
29,166 (+0.35%) |
Filing |
| 2021-07-12 5:13 pm Purchase |
2021-07-02 | 13D | Aerovate Therapeutics, Inc. AVTE |
RA Capital Management, L.P. | 8,263,982 33.900% |
8,263,982 (New Position) |
Filing |